📊 CMPX Key Takeaways
Investment Thesis
Compass Therapeutics is a pre-revenue biotech company burning substantial cash with negative operating cash flow of -$49.1M annually against minimal cash reserves of $30.6M, indicating a critical funding timeline. The company is unable to sustain operations without external financing, and at current burn rates faces less than 8 months of runway without additional capital.
CMPX Strengths
- Strong balance sheet with zero long-term debt and $196.8M stockholders equity provides capital structure flexibility
- Excellent liquidity position with 15.02x current ratio demonstrates ability to meet short-term obligations
- Low financial leverage (0.0x debt-to-equity) reduces insolvency risk during drug development phase
CMPX Risks
- Zero revenue with 100% YoY revenue decline indicates no commercial product traction or FDA approvals
- Severe cash burn of -$49.1M in operating cash flow against only $30.6M in liquid reserves creates immediate solvency risk
- Negative ROE (-33.8%) and ROA (-30.3%) demonstrate the company is destroying shareholder value at an accelerating rate
- Net losses of -$66.5M indicate R&D spending is not yielding revenue-generating outcomes
- Pre-clinical/clinical stage biotech with no path to profitability visible in financial data
Key Metrics to Watch
- Cash burn rate and months of runway remaining before funding requirement
- Clinical trial progression and FDA milestone announcements
- Operating cash flow trajectory and capital raise announcements
CMPX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 15.02x current ratio provides a solid financial cushion.
CMPX Profitability Ratios
CMPX vs Healthcare Sector
How Compass Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CMPX Balance Sheet & Liquidity
CMPX 5-Year Financial Trend
5-Year Trend Summary: Compass Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.36 indicates the company is currently unprofitable.
CMPX Growth Metrics (YoY)
CMPX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$10.5M | $-0.08 |
| Q2 2025 | N/A | -$10.8M | $-0.10 |
| Q3 2024 | N/A | -$7.8M | $-0.08 |
| Q2 2024 | N/A | -$7.8M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CMPX Capital Allocation
CMPX SEC Filings
Access official SEC EDGAR filings for Compass Therapeutics, Inc. (CIK: 0001738021)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CMPX
What is the AI rating for CMPX?
Compass Therapeutics, Inc. (CMPX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CMPX's key strengths?
Strong balance sheet with zero long-term debt and $196.8M stockholders equity provides capital structure flexibility. Excellent liquidity position with 15.02x current ratio demonstrates ability to meet short-term obligations.
What are the risks of investing in CMPX?
Zero revenue with 100% YoY revenue decline indicates no commercial product traction or FDA approvals. Severe cash burn of -$49.1M in operating cash flow against only $30.6M in liquid reserves creates immediate solvency risk.
What is CMPX's revenue and growth?
Compass Therapeutics, Inc. reported revenue of $0.0.
Does CMPX pay dividends?
Compass Therapeutics, Inc. does not currently pay dividends.
Where can I find CMPX SEC filings?
Official SEC filings for Compass Therapeutics, Inc. (CIK: 0001738021) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CMPX's EPS?
Compass Therapeutics, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.